Hepatocellular adenoma (HCA) are benign liver tumours that may be complicated by haemorrhage or malignant transformation to hepatocellular carcinoma. Epidemiological data are fairly outdated, but it is likely to assume that the incidence has increased over the past decades as HCA are more often incidentally found due to the more widespread use of imaging techniques and the increased incidence of obesity. Various molecular subgroups have been described. Each of these molecular subgroups are defined by specific gene mutations and pathway activations. Additionally, they are all related to specific risk factors and show a various biological behaviour. These molecular subgroups may be identified using immunohistochemistry and molecular characterization. Contrast‐enhanced MRI is the recommended imaging modality to analyse patients with suspected hepatocellular adenoma allowing to determine the subtype in up to 80%. Surgical resection remains to be the golden standard in treating HCA, although resection is deemed unnecessary in a large number of cases, as studies have shown that the majority of HCA will regress over time without complications such as haemorrhage or malignant transformation occurring. It is preferable to treat patients with suspected HCA in high volume centres with combined expertise of liver surgeons, hepatologists, radiologists and (molecular) pathologists.

中文翻译：

---

肝细胞腺瘤治疗的新见解。

肝细胞腺瘤（HCA）是良性肝肿瘤，可能会因出血或恶性转化为肝细胞癌而并发。流行病学数据已经过时，但是很可能会假设过去几十年来发病率有所增加，因为由于成像技术的广泛使用和肥胖症的发生率更高，偶然发现了HCA。已经描述了各种分子亚组。这些分子亚组中的每一个都由特定的基因突变和途径激活定义。此外，它们都与特定的危险因素有关，并表现出各种生物学行为。这些分子亚组可以使用免疫组织化学和分子表征来鉴定。建议使用对比增强MRI来分析可疑肝细胞腺瘤患者的影像学方式，从而确定多达80％的亚型。手术切除仍然是治疗HCA的黄金标准，尽管在许多情况下，手术切除被认为是不必要的，因为研究表明，大多数HCA会随着时间的推移而消退，而不会发生出血或恶性转化等并发症。最好是在肝脏外科医师，肝病学家，放射学家和（分子）病理学家的共同专长下，在大容量中心治疗可疑HCA患者。研究表明，大多数HCA会随着时间的推移而消退，而不会发生诸如出血或恶性转化等并发症。最好是在肝脏外科医师，肝病学家，放射学家和（分子）病理学家的共同专长下，在大容量中心治疗可疑HCA患者。研究表明，大多数HCA会随着时间的推移而消退，而不会发生诸如出血或恶性转化等并发症。最好是在肝脏外科医师，肝病学家，放射学家和（分子）病理学家的共同专长下，在大容量中心治疗可疑HCA患者。